Embecta Corp. (EMBC) fair value analysis
Nasdaq · Updated 2026-09-07
Embecta Corp. is a healthcare company that manufactures and distributes insulin delivery devices, pen needles, and other injection products used by patients with diabetes. The company operates globally, serving customers across multiple continents through its portfolio of medical devices designed to improve the administration of injectable medications.
Forward Fair Value verdict
UndervaluedBased on TickrTrends' weekly Forward Fair Value model, EMBC is trading at more than a 25% discount to estimated fair value.
EMBC currently ranks #3 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.
- Last price
- $3.72
- Sector
- Healthcare
- 12-month range
- $3.29–$14.27
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- C-
- Momentum grade
- B
- Leverage
- Low
- RSI zone
- Overbought
- 50/200-day trend
- Downtrend
- 52-week position
- The bottom quarter of its range
What our data shows for EMBC
- Our model validated 8 trailing price-to-earnings windows for EMBC, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $3.29–$14.27.
- The 14-day relative strength index sits at an overbought 80.
- 3 of the last 12 weekly snapshots showed positive price momentum.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for EMBC
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
What people are saying
Follow the EMBC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — EMBC's momentum rating declined from A to B this week, while its RSI zone shifted from neutral to overbought territory. The stock maintains an undervalued valuation verdict within the Healthcare sector. These changes suggest a loss of upward momentum despite price strength reaching overbought levels.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is EMBC stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), EMBC is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is EMBC's TickrTrends verdict?
EMBC's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does EMBC compare to other Healthcare stocks?
EMBC ranks #3 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.
Is EMBC overbought or oversold?
EMBC's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
More in Healthcare
Head-to-head comparisons
EMBC vs ADMA · EMBC vs ALGN · EMBC vs ASTH · EMBC vs AZN · EMBC vs BSX